These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial. Tanum L; Solli KK; Latif ZE; Benth JŠ; Opheim A; Sharma-Haase K; Krajci P; Kunøe N JAMA Psychiatry; 2017 Dec; 74(12):1197-1205. PubMed ID: 29049469 [TBL] [Abstract][Full Text] [Related]
6. Extended-Release Injection vs Sublingual Buprenorphine for Opioid Use Disorder With Fentanyl Use: A Post Hoc Analysis of a Randomized Clinical Trial. Nunes EV; Comer SD; Lofwall MR; Walsh SL; Peterson S; Tiberg F; Hjelmstrom P; Budilovsky-Kelley NR JAMA Netw Open; 2024 Jun; 7(6):e2417377. PubMed ID: 38916892 [TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers. Sigmon SC; Dunn KE; Saulsgiver K; Patrick ME; Badger GJ; Heil SH; Brooklyn JR; Higgins ST JAMA Psychiatry; 2013 Dec; 70(12):1347-54. PubMed ID: 24153411 [TBL] [Abstract][Full Text] [Related]
8. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial. Fiellin DA; Schottenfeld RS; Cutter CJ; Moore BA; Barry DT; O'Connor PG JAMA Intern Med; 2014 Dec; 174(12):1947-54. PubMed ID: 25330017 [TBL] [Abstract][Full Text] [Related]
9. A trial of integrated buprenorphine/naloxone and HIV clinical care. Sullivan LE; Barry D; Moore BA; Chawarski MC; Tetrault JM; Pantalon MV; O'Connor PG; Schottenfeld RS; Fiellin DA Clin Infect Dis; 2006 Dec; 43 Suppl 4():S184-90. PubMed ID: 17109305 [TBL] [Abstract][Full Text] [Related]
10. Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. Montoya ID; Gorelick DA; Preston KL; Schroeder JR; Umbricht A; Cheskin LJ; Lange WR; Contoreggi C; Johnson RE; Fudala PJ Clin Pharmacol Ther; 2004 Jan; 75(1):34-48. PubMed ID: 14749690 [TBL] [Abstract][Full Text] [Related]
11. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre. Stimolo C; Favero VD; Zecchinato G; Buson R; Cusin D; Pellachin P; Simonetto P Clin Drug Investig; 2010; 30 Suppl 1():27-31. PubMed ID: 20450243 [TBL] [Abstract][Full Text] [Related]
12. A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Johnson RE; Eissenberg T; Stitzer ML; Strain EC; Liebson IA; Bigelow GE Drug Alcohol Depend; 1995 Nov; 40(1):17-25. PubMed ID: 8746920 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of an injection depot formulation of buprenorphine: placebo comparison. Sigmon SC; Wong CJ; Chausmer AL; Liebson IA; Bigelow GE Addiction; 2004 Nov; 99(11):1439-49. PubMed ID: 15500597 [TBL] [Abstract][Full Text] [Related]
14. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. Woody GE; Poole SA; Subramaniam G; Dugosh K; Bogenschutz M; Abbott P; Patkar A; Publicker M; McCain K; Potter JS; Forman R; Vetter V; McNicholas L; Blaine J; Lynch KG; Fudala P JAMA; 2008 Nov; 300(17):2003-11. PubMed ID: 18984887 [TBL] [Abstract][Full Text] [Related]
15. Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers. Strain EC; Stoller K; Walsh SL; Bigelow GE Psychopharmacology (Berl); 2000 Mar; 148(4):374-83. PubMed ID: 10928310 [TBL] [Abstract][Full Text] [Related]
16. Therapeutic switch to buprenorphine/naloxone from buprenorphine alone: clinical experience in an Italian addiction centre. Montesano F; Zaccone D; Battaglia E; Genco F; Mellace V Clin Drug Investig; 2010; 30 Suppl 1():13-9. PubMed ID: 20450241 [TBL] [Abstract][Full Text] [Related]
17. Desipramine in opioid-dependent cocaine abusers maintained on buprenorphine vs methadone. Oliveto AH; Feingold A; Schottenfeld R; Jatlow P; Kosten TR Arch Gen Psychiatry; 1999 Sep; 56(9):812-20. PubMed ID: 12884887 [TBL] [Abstract][Full Text] [Related]
18. A randomized controlled trial of buprenorphine taper duration among opioid-dependent adolescents and young adults. Marsch LA; Moore SK; Borodovsky JT; Solhkhah R; Badger GJ; Semino S; Jarrett K; Condon KD; Rossettie K; Vincent P; Hajizadeh N; Ducat E Addiction; 2016 Aug; 111(8):1406-15. PubMed ID: 26918564 [TBL] [Abstract][Full Text] [Related]
19. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study. Landau CJ; Carr WD; Razzetti AJ; Sessler NE; Munera C; Ripa SR Clin Ther; 2007 Oct; 29(10):2179-93. PubMed ID: 18042474 [TBL] [Abstract][Full Text] [Related]